AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM184.68+2.15 (+1.18%) ▲|QCOM176.10+7.36 (+4.36%) ▲|RTX198.64-2.16 (-1.07%) ▼|SBUX102.87-1.60 (-1.53%) ▼|SCHW108.08-1.22 (-1.11%) ▼|SO89.01+0.90 (+1.02%) ▲|SPG209.60+0.16 (+0.08%) ▲|T25.72+0.04 (+0.17%) ▲|TMO600.83-12.95 (-2.11%) ▼|TMUS180.58-0.94 (-0.52%) ▼|TSLA366.87+12.79 (+3.61%) ▲|TXN259.90+1.46 (+0.56%) ▲|UBER73.45-2.32 (-3.06%) ▼|UNH395.99-1.15 (-0.29%) ▼|UNP289.92+0.30 (+0.10%) ▲|UPS101.22-1.07 (-1.05%) ▼|USB62.86-0.52 (-0.81%) ▼|V368.13-6.94 (-1.85%) ▼|VZ50.32+0.18 (+0.35%) ▲|WFC88.76-1.22 (-1.35%) ▼|WMT106.06-1.08 (-1.01%) ▼|XOM159.62+0.15 (+0.09%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

GELITA Showcases Advanced Excipient Solutions at BIO International- June 2025 in Boston

EBERBACH, Germany, June 9, 2025 /PRNewswire/ -- GELITA, a global leader in pharmaceutical gelatin and collagen peptide solutions, is proud to announce its participation...

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")...

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

National TV Segment Highlights FDA-Approved Treatment for Rosacea

GUINNESS WORLD RECORDS™ attempt by Parmigiano Reggiano and Loblaw Companies Ltd. to crack the most Parmigiano Reggiano wheels simultaneously

Parmigiano Reggiano and Loblaw Companies Ltd. partner to break their own GUINNESS WORLD RECORDS title in the cracking of more than 1,800 wheels at over 450 grocery stores across Canada 
Parmigiano Reggiano and Loblaw Companies Ltd. partner to break their own GUINNESS WORLD RECORDS title in the cracking of more than 1,800 wheels at over 450 grocery stores across Canada

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts

Okomera Opens Pre-orders for Ocentra, the Central Engine for Automated Organoid Screening

PARIS, June 9, 2025 /PRNewswire/ -- Okomera, a biotech pioneering automated organoid-based drug discovery, today opened pre-orders for its first commercial system, Ocentra, unveiled live...

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well...

Excipients Strategic Business Report 2025: Global Market to Reach $10.2 Billion by 2030 – Expansion of Generic Drugs Boost Demand, Biologics and Biosimilars Influencing...

The global Excipients Market, valued at $7.8 Billion in 2024, is projected to reach $10.2 Billion by 2030, growing at a CAGR of 4.6%. This comprehensive report analyzes key trends, drivers, and forecasts, emphasizing the essential role of excipients in pharmaceutical formulations. Discover how excipients enhance drug efficacy and patient experience, explore innovations like multifunctional excipients, and gain insights into regional growth trends, notably in the U.S. and China. 
The global Excipients Market, valued at $7.8 Billion in 2024, is projected to reach $10.2 Billion by 2030, growing at a CAGR of 4.6%. This comprehensive report analyzes key trends, drivers, and forecasts, emphasizing the essential role of excipients in pharmaceutical formulations. Discover how excipients enhance drug efficacy and patient experience, explore innovations like multifunctional excipients, and gain insights into regional growth trends, notably in the U.S. and China.

WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu

The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches...

AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai

Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. 
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry.

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™...

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small...

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers